SCHEMBL9486237

SCHEMBL9486237

Cc1cnc(N2CCNCC2)nc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.54
CYP1A2 P05177 11/20 0.54
HSD17B10 Q99714 10/20 0.54
CASP1 P29466 9/20 0.54
CASP7 P55210 8/20 0.54
HPGD P15428 7/20 0.54
CYP3A4 P08684 6/20 0.54
CYP2C19 P33261 4/20 0.54
TSHR P16473 3/20 0.54
USP2 O75604 6/20 0.49
KDM4E B2RXH2 1/20 0.47
HRH1 P35367 1/20 0.46
CHRNB2 P17787 1/20 0.45
CHRNA4 P43681 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
ADRB1 P08588 1/20 0.44
CASP4 P49662 1/20 0.43
CASP5 P51878 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8579574 0.98 ALDH1A1 (0.52) ALDH1A1CYP1A2HSD17B10CASP1CASP7
Hydrochloric Acid SCHEMBL10410648 0.98 ALDH1A1 (0.52) ALDH1A1CYP1A2HSD17B10CASP1CASP7
Hydrochloric Acid SCHEMBL18153368 0.97 ALDH1A1 (0.51) ALDH1A1CYP1A2HSD17B10CASP1CASP7
SCHEMBL21551156 0.86 ALDH1A1 (0.51) ALDH1A1CYP1A2HSD17B10CASP1CASP7
SCHEMBL18005507 0.83 POLB (0.54) ALDH1A1CYP1A2HSD17B10TSHRUSP2
SCHEMBL1708343 0.83 POLB (0.58) ALDH1A1TSHRSMN1; SMN2POLBMAPK1
SCHEMBL20804679 0.83 ALDH1A1 (0.51) ALDH1A1CYP1A2HSD17B10CASP1CASP7
Hydrochloric Acid SCHEMBL25309917 0.81 CHRNB2 (0.53) ALDH1A1CYP1A2HSD17B10CASP1CASP7
SCHEMBL21564400 0.80 ALDH1A1 (0.53) ALDH1A1CYP1A2HSD17B10CASP1CASP7
SCHEMBL17066352 0.80 HTR3A (0.54) ALDH1A1CYP1A2HSD17B10CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130273034-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO EARLY DISCOVERY, INC. 2013-10-17 US disclosed
WO-2013078254-A1 BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-05-30 WO disclosed
US-5204465-A PROCESS FOR THE PRODUCTION OF PIPERAZINYLPYRIMIDINE DERIVATIVES LONZA LTD. (CH) 1993-04-20 US disclosed
EP-0491329-A1 Process for the preparation of piperazinyl-pyrimidin derivatives LONZA AG (CH) 1992-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130273034-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 ALDH1A1 1273/4885CYP1A2 2270/4885HSD17B10 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.